APVO APVO
Company Profile ↓Company Overview
APVO (APVO) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue -74.7%.
- 5-Year Trend Long-term compounding — revenue CAGR -28.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -28.81% |
| 1 Year: | -74.67% |
Stock Price Performance
| 1 Year: | -91.01% |
| 6 Months: | -38.02% |
| 3 Months: | -21.68% |
| 1 Month: | -7.10% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)45.45 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -28.8% CAGR over 5 years.
- Trading 91.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | 3.53M | 6.17M | 4.07M | 6.83M | 5.82M | 7.02M | 7.36M | 9.01M | - | 473.00K | 1.46M | 2.42M | 3.11M | 3.10M | 3.11M | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -11.10M | -18.31M | -13.19M | -18.50M | -12.98M | -12.85M | -90.53M | -14.55M | -12.13M | -14.65M | -10.35M | -13.50M | -12.44M | -12.13M | -11.44M | -12.90M | -11.46M | -7.62M | -6.81M | -6.25M | -6.89M | -5.72M | -4.75M | -5.61M | -7.56M | -7.78M | -7.76M | -8.18M | -6.56M | -6.98M | -6.02M | -5.21M | -6.48M | -6.23M | -7.61M | -6.84M |
| Net Income | -11.02M | -17.72M | -12.68M | -17.90M | -12.89M | -12.84M | -71.74M | -14.95M | -9.95M | -11.19M | 37.87M | -13.85M | -13.14M | -12.56M | -12.02M | -13.33M | -6.92M | 2.90M | -6.80M | -6.79M | -7.26M | -7.93M | -7.00M | -7.70M | 28.01M | -7.64M | 2.77M | -7.95M | -6.33M | -6.83M | -5.88M | -5.10M | -6.41M | -6.20M | -7.55M | -6.70M |
| Diluted EPS | - | - | - | - | - | - | -3.55 | - | - | - | 1.75 | - | - | -0.56 | - | - | - | - | - | - | - | -1.75 | -1.43 | -1.55 | 5.58 | -1.50 | 17.38 | -53.95 | -22.16 | -368.21 | -1,236.96 | -357.86 | -1,581.81 | -8.40 | -2.23 | -6.41 |
| R&D Expense | - | - | 7.71M | - | 8.10M | 7.64M | 7.08M | - | 5.87M | 6.79M | 7.17M | 8.20M | 9.71M | 8.57M | 6.63M | 6.12M | 7.60M | 4.01M | 4.44M | 4.49M | 5.36M | 4.72M | 4.37M | 4.87M | 3.87M | 4.48M | 4.17M | 5.46M | 3.89M | 3.75M | 3.64M | 3.10M | 3.63M | 3.33M | 4.04M | 3.92M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 33.60M | 9.98M | 14.66M | 23.07M | 32.42M | 4.31M | 12.29M | 3.11M | - | - | - |
| Operating Income | -61.10M | -138.77M | -53.95M | -51.66M | -40.96M | -27.49M | -21.40M | -28.64M | -28.88M | -24.60M | -26.31M |
| Net Income | -59.32M | -112.42M | 6.97M | -53.69M | -40.45M | -17.75M | -28.46M | 8.03M | -17.41M | -24.13M | -25.97M |
| Diluted EPS | - | - | - | - | - | - | -6.07 | 1.57 | -2,316.83 | -31,460.23 | -87.27 |
| R&D Expense | 34.73M | 29.12M | 29.02M | 35.38M | 24.76M | 17.85M | 18.99M | 17.88M | 17.11M | 14.38M | 14.54M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2014 | Dec 2015 | Mar 2016 | Jun 2016 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 127.77M | 127.92M | 133.47M | 91.86M | 117.01M | 67.49M | 53.41M | 53.55M | 56.60M | 34.22M | 24.84M | 15.59M | 27.19M |
| Total Equity | 94.61M | 88.62M | 89.86M | 97.20M | 50.57M | 82.03M | 30.41M | 11.84M | 16.59M | 1.22M | 17.97M | 12.22M | 4.75M | 17.38M |
| Cash & Equivalents | 3.59M | 4.64M | - | - | 9.68M | 7.09M | 30.64M | 12.45M | 39.98M | 45.04M | 22.64M | 16.90M | 8.71M | 21.62M |
| Long Term Debt | - | - | - | - | 18.38M | 15.73M | 19.28M | - | 28.22M | 3.71M | 1.46M | 0 | - | - |
| Total Liabilities | - | 39.15M | 38.05M | 36.27M | 41.29M | 34.97M | 37.09M | 41.57M | 36.95M | 55.38M | 16.24M | 12.62M | 10.84M | 9.81M |
| Current Liabilities | - | 19.94M | - | - | 19.54M | 18.51M | 17.61M | 38.24M | 14.54M | 34.76M | 8.71M | 7.22M | 6.21M | 6.05M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | -41.57M | -51.42M | -42.38M | -29.32M | -21.68M | -21.02M | -11.73M | -23.79M | -25.59M |
| Investing Cash Flow | - | - | 29.46M | 72.80M | 4.10M | 28.03M | -713.00K | -29.00K | 0 | 0 | 0 |
| Financing Cash Flow | - | - | 19.53M | -787.00K | 20.15M | 23.87M | 26.16M | -2.62M | 6.00M | 15.60M | 38.50M |
| Capital Expenditure | -1.53M | -2.51M | -1.40M | -976.00K | -153.00K | -88.00K | -713.00K | -29.00K | - | - | - |
| Free Cash Flow | - | - | -42.98M | -52.40M | -42.54M | -29.41M | -22.39M | -21.05M | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | -181.8% | -1,389.8% | -368.1% | -224.0% | -126.3% | -638.1% | -174.1% | -919.7% | - | - | - |
| Net Margin % | -176.5% | -1,125.8% | 47.6% | -232.8% | -124.7% | -411.9% | -231.5% | 257.8% | - | - | - |
| ROE % | -66.9% | -222.3% | 8.5% | -176.6% | -341.6% | -107.0% | -2,340.2% | 44.7% | -142.5% | -507.5% | -149.4% |
| ROCE % | -56.7% | -191.9% | -54.8% | -103.6% | -270.0% | -70.5% | -98.0% | -112.3% | -163.9% | -262.2% | -124.4% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for APVO
6 AML patients reached transplant as Aptevo enters final dose stage - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxNdEpjNGF4Q2J6eG55NDRvZThuUjNzV3B4ZTF5VXUwclU4R0dhOEk2bWVhM0dJX1M5ajlTOEI4OGxwWDRYSHdvdDNiTDUxcDJJLVlvSXh1RTNlYzNfMi11Z2Rwa2liR2QySEY2RWNMamwyNENMUVpydVBoUHcxQUdnTHJVRWhfb196Wktidk…
APVO Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTFBSSGNiVkNvdktRY3hWU3llWXRCYXgyT1U0WXA4OEFrcUVQNFRRVENmcnpGOGg0RUJ3U1M0dDZuMm0zSHhaUEc0VVRJZjlkWmwzM3lVY2MzLTF6Y2xKdTR1YjhkYVE0QzhlN2RjQmdXaS1kd2hHZ3FoUEJn?oc=5" target="_blank">APV…
APVO|Aptevo Therapeutics Inc|Price:3.945|Chg%:-0.165 - TradingKey
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE5vT0dKSGF3UDVzV2Q4bVhtNmt2Q3htTFZ2NDZ4LTA4LW9PeEtYZ1NTR2ozNkNVNkVxYl94eUxmU2V1djR1clIzb1dWOVNiWGF5Q3NnNTlPcS1xUFlWeHp5RGdXLU1PSkJ3YVZFcGNn?oc=5" target="_blank">APVO|Aptevo Therape…
$APVO stock is down 9% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxQSElwZEktd3dYNzJyR2hxU2RoRDNyaDZzeFRJLXRSNHI2dEgyejQwMmVmdlV3TjR0Y1owUkFndFdxckJGSFhNeDRzYUVwaG9KYmdKTC1rZ3cwUWtLTVZCcWNmRVZVQ1pRVEltMEl4cFhRSHAxMHRvWnYzdjdOaDdhZlB5bXRlU3B0Z0htd2…
Aptevo Therapeutics (APVO) Upgraded to Buy: Here's Why - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxOY1prZGpabUs5ck5vZXB0blhDQVNZWmtucEdlZF9zQWRJSkxGb3d6R2kzemZXVG9leUtQeEpTVS1yQU9waTgtbmNLSnRnd21xU3NhWjhVeVlKOUlSLUI2eHhHRHgyLTNBdUVneHdacXo3RzNjNm53elV1TWtURElZZGJfVHpYNjNGQVVJeT…
Aptevo Filing May Support Radiopharmaceuticals and T-Cell Engagers - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxPTHFGdXV5LVkwc0hQeFF1di1xcloyLTFmMXEta0ZLV3lSUmJ2THFwdmk5Vm56NjkyME5fUVpqOTBEYUFIOVJoS0pyNFA3T0FkckNHdVVDQmEtaEtNYVJ1dHdEb0NzNUlqMDFXVVJVRXQ1aHZnYTlfS2JUb0JRbGZBb1h5aENxT3YyLXVkX2…
APVO — Frequently Asked Questions
What is the current share price of APVO?
As of 2026-08-05 17:25 PDT, APVO trades at $4.19 on NASDAQ/NYSE. Its 52-week range is $3.94 to $46.62.
What is the P/E ratio of APVO?
APVO trades at a trailing price-to-earnings (P/E) ratio of -0.05.
What is the return on equity (ROE) of APVO?
APVO has a return on equity (ROE) of -149.40%. Its return on capital employed (ROCE) is -124.44%.
Is APVO a good stock to buy?
This page provides a data-driven analysis of APVO, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.